Treating Rare Life-threatening Liver Diseases
Versantis developed drugs and diagnostics for the treatment of acute and chronic liver failure with the aim of revolutionizing previous standards of care. The lead project VS-01 was in pre-clinical phase 2 at exit with the potential to become a first-line therapy for chronic liver failure. Versantis was acquired by GENFIT in September 2022 to jointly continue the development of its revolutionary therapeutics.